Direct-to-consumer health startup Ro has partnered with Eli Lilly to provide more affordable single-dose vials of the weight-loss drug Zepbound, streamlining access through a seamless platform. The initiative integrates Ro’s services with LillyDirect, enabling eligible patients to receive diagnoses, prescriptions, and home delivery of Zepbound via Gifthealth. Ro states that Zepbound vials offer the lowest price for a branded GLP-1 drug before insurance. Demand for GLP-1 medications, which help control appetite and blood sugar, has surged over the past two years.